Keywords
Abstract
The researches, devoted to the treatment of COPD because of its huge spread, high incidence of disability and growing mortality, are actual. According to some studies mucoregulatory means primarily thiol derivatives in the treatment of COPD 3-4 degree of severity are able to reduce the frequency of exacerbations and improve quality of life for patients. In the study the clinical efficacy and effect of the«peroxidation» lipids activity as an index of airway mucosal inflammation during systemic treatment by carbotsisteine with prolonged (12 months) combination with bronchodilator therapy in 40 patients with COPD 2 degree of severity, divided into two equal groups, were evaluated. According to the study in patients with COPD 2 degree of severity karbotsistein reception along with bronchodilator therapy has the 6th month of treatment was a decrease in the intensity of cough and dyspnea, increased exercise tolerance, and improvement in FEV1 by spirometry. The rate of exacerbation frequency in this group of patients has decreased during one year, which can be explained by antioxidant action of karbotsistein, which gives indirectlya more pronounced anti-inflammatory effect throughout the therapy. The criteria for appointment and / or revocation of karbotsisteina COPD patients 2 degree of severity can be a dynamic activity of antioxidant enzymes, particularly thermostable catalase fraction, which is a reliable measure of the severity of «oxidative stress».